Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.60 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.60 |
| ▸ | PARP1 | P09874 | 4/20 | 0.60 |
| ▸ | TNKS | O95271 | 1/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233768 | 0.79 | ALDH1A1 (1.00) | KMT2AALDH1A1MEN1MAPK1TNKS2 | |
| SCHEMBL29478203 | 0.75 | TNKS2 (1.00) | KMT2AALDH1A1MEN1MAPK1TNKS2 | |
| SCHEMBL422013 | 0.75 | TNKS2 (1.00) | KMT2AALDH1A1MEN1MAPK1TNKS2 | |
| SCHEMBL10926777 | 0.73 | — | — | |
| SCHEMBL15691453 | 0.73 | — | — | |
| SCHEMBL16155977 | 0.70 | PARP1 (0.50) | KMT2AALDH1A1MEN1MAPK1TNKS2 | |
| SCHEMBL1549733 | 0.69 | TNKS2 (0.62) | KMT2AALDH1A1MEN1MAPK1TNKS2 | |
| SCHEMBL1549073 | 0.69 | TNKS2 (0.67) | KMT2AALDH1A1MEN1MAPK1TNKS2 | |
| SCHEMBL16472188 | 0.69 | TNKS2 (0.67) | KMT2AALDH1A1MEN1MAPK1TNKS2 | |
| SCHEMBL1549859 | 0.67 | TNKS2 (0.60) | KMT2AALDH1A1MEN1MAPK1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | claimed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | claimed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| EP-0991653-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-04-12 | — | — | EP | claimed |
| WO-1998054190-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | claimed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2025262243-A1 | THIENO- AND THIAZOLOPYRIMIDINE-2,6-DIONES AND USE THEREOF AS IMMUNOMODULATORS | INVIOS GMBH (AT) | 2025-12-26 | — | — | WO | disclosed |
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4568971-A1 | ANTAGONISTS OF 5-HYDROXYTRYPTAMINE RECEPTOR SUBTYPE 2B | Vanderbilt University (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025111492-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-4707550-A | N-(substituted thienyl)-N'-(substituted piperazinyl)-ureas | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0244176-A2 | Thienopyrimidine-2,4-dione derivatives and intermediates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4670560-A | VASODILATING AGENTS, HYPOTENSIVE AGENTS AND/OR CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-02 | — | — | US | disclosed |
| US-4196207-A | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks | ICI AUSTRALIA LIMITED | 1980-04-01 | — | — | US | disclosed |
| US-4146716-A | PLANT GROWTH REGULATORS, FUNGICIDES, BACTERICIDES, VIRICIDES, INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | KMT2A 2454/4885ALDH1A1 1766/4885MEN1 1664/4885 |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | KMT2A 2228/4885ALDH1A1 4514/4885MEN1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.